ArticleProceedings of the National Academy of Sciences of the United States of America2021

A highly selective and potent CXCR4 antagonist for hepatocellular carcinoma treatment.

Jen-Shin Song et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.